MA32283B1 - Composes cycliques condenses et utilisation de ceux-ci - Google Patents

Composes cycliques condenses et utilisation de ceux-ci

Info

Publication number
MA32283B1
MA32283B1 MA33304A MA33304A MA32283B1 MA 32283 B1 MA32283 B1 MA 32283B1 MA 33304 A MA33304 A MA 33304A MA 33304 A MA33304 A MA 33304A MA 32283 B1 MA32283 B1 MA 32283B1
Authority
MA
Morocco
Prior art keywords
cyclic compounds
condensed cyclic
relates
present
glucokinase activator
Prior art date
Application number
MA33304A
Other languages
Arabic (ar)
English (en)
Inventor
Tsuneo Yasuma
Nobuyuki Takakura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32283B1 publication Critical patent/MA32283B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne un activateur de glucokinase utile en tant qu'agent pharmaceutique tel qu'un agent pour la prophylaxie ou le traitement du diabète, de l'obésité et similaire. La présente invention concerne un activateur de glucokinase contenant un composé représenté par la formule (i) : dans laquelle chaque symbole est défini dans la spécification, ou un sel de celui-ci ou un promédicament de celui-ci.
MA33304A 2008-04-10 2010-11-01 Composes cycliques condenses et utilisation de ceux-ci MA32283B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10
PCT/JP2009/057625 WO2009125873A1 (fr) 2008-04-10 2009-04-09 Composés cycliques condensés et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
MA32283B1 true MA32283B1 (fr) 2011-05-02

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33304A MA32283B1 (fr) 2008-04-10 2010-11-01 Composes cycliques condenses et utilisation de ceux-ci

Country Status (34)

Country Link
US (1) US8673942B2 (fr)
EP (1) EP2276760B1 (fr)
JP (1) JP5528348B2 (fr)
KR (1) KR20110002472A (fr)
CN (1) CN102056924B (fr)
AR (1) AR073609A1 (fr)
AU (1) AU2009234666B2 (fr)
BR (1) BRPI0910912A2 (fr)
CA (1) CA2720686A1 (fr)
CO (1) CO6321240A2 (fr)
CR (1) CR11730A (fr)
CY (1) CY1115247T1 (fr)
DK (1) DK2276760T3 (fr)
DO (1) DOP2010000301A (fr)
EA (1) EA019640B1 (fr)
EC (1) ECSP10010602A (fr)
ES (1) ES2476265T3 (fr)
GE (1) GEP20135846B (fr)
HR (1) HRP20140588T1 (fr)
IL (1) IL208463A (fr)
MA (1) MA32283B1 (fr)
ME (1) ME01887B (fr)
MX (1) MX2010011138A (fr)
MY (1) MY152475A (fr)
NZ (1) NZ588562A (fr)
PE (1) PE20100734A1 (fr)
PL (1) PL2276760T3 (fr)
PT (1) PT2276760E (fr)
RS (1) RS53378B (fr)
SI (1) SI2276760T1 (fr)
UA (1) UA104422C2 (fr)
UY (1) UY32131A (fr)
WO (1) WO2009125873A1 (fr)
ZA (1) ZA201007682B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371826A4 (fr) 2008-12-29 2012-06-27 Takeda Pharmaceutical Nouveau composé cyclique condensé et utilisation de celui-ci
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
WO2014099578A1 (fr) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Nouveaux composés activateurs de glucokinase, compositions contenant de tels composés, et méthodes de traitement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015301A1 (fr) 1991-03-01 1992-09-17 H. Lundbeck A/S Traitement de l'hypertension et de maladies vasculaires peripheriques
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
JPWO2003103648A1 (ja) 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 糖尿病治療薬
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
WO2006089397A1 (fr) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Procédés pour traiter l’arthrite à l’aide de composés trihétérocycliques
EP2308839B1 (fr) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Composés hétérocycliques condensés
AU2006295645B2 (en) 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
WO2009025478A1 (fr) 2007-08-17 2009-02-26 Lg Life Sciences Ltd. Composés d'indole et d'indazole en tant qu'inhibiteurs de nécrose cellulaire
CN101896483B (zh) * 2007-12-20 2013-11-20 株式会社Lg生命科学 葡糖激酶激活剂和包含其作为活性成分的药物组合物
JP5188583B2 (ja) * 2008-01-04 2013-04-24 エルジー・ライフ・サイエンシーズ・リミテッド 細胞、組織及び臓器保存効果を有するインドール及びインダゾール誘導体
EP2371826A4 (fr) 2008-12-29 2012-06-27 Takeda Pharmaceutical Nouveau composé cyclique condensé et utilisation de celui-ci

Also Published As

Publication number Publication date
CO6321240A2 (es) 2011-09-20
JP5528348B2 (ja) 2014-06-25
JP2011516403A (ja) 2011-05-26
EA019640B1 (ru) 2014-05-30
PE20100734A1 (es) 2010-11-18
UY32131A (es) 2010-11-30
PT2276760E (pt) 2014-05-28
AR073609A1 (es) 2010-11-17
EP2276760B1 (fr) 2014-04-09
AU2009234666B2 (en) 2014-02-20
UA104422C2 (uk) 2014-02-10
ES2476265T3 (es) 2014-07-14
MY152475A (en) 2014-10-15
EA201071180A1 (ru) 2011-04-29
IL208463A0 (en) 2010-12-30
CY1115247T1 (el) 2017-01-04
DOP2010000301A (es) 2010-12-31
MX2010011138A (es) 2010-11-12
ZA201007682B (en) 2011-12-28
RS53378B (sr) 2014-10-31
AU2009234666A1 (en) 2009-10-15
US20110098297A1 (en) 2011-04-28
GEP20135846B (en) 2013-06-10
EP2276760A1 (fr) 2011-01-26
HRP20140588T1 (hr) 2014-08-01
US8673942B2 (en) 2014-03-18
CA2720686A1 (fr) 2009-10-15
KR20110002472A (ko) 2011-01-07
PL2276760T3 (pl) 2014-09-30
WO2009125873A1 (fr) 2009-10-15
SI2276760T1 (sl) 2014-05-30
NZ588562A (en) 2012-07-27
IL208463A (en) 2015-07-30
CN102056924B (zh) 2014-05-21
DK2276760T3 (da) 2014-05-26
CR11730A (es) 2010-12-08
CN102056924A (zh) 2011-05-11
HK1152932A1 (en) 2012-03-16
ECSP10010602A (es) 2011-03-31
ME01887B (me) 2014-12-20
BRPI0910912A2 (pt) 2015-08-11

Similar Documents

Publication Publication Date Title
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
MA30890B1 (fr) Compose indole
MA34713B1 (fr) Compose bicyclique
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA32171B1 (fr) Compose heterocyclique
MA65131B1 (fr) Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t
MA32965B1 (fr) Derives de sulfonamides
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
MA39247B1 (fr) 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA35611B1 (fr) Composé inhibiteur de la signalisation par la voie notch
MA31419B1 (fr) Derives de pyridine
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA29926B1 (fr) Derives de pyrazine
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2018182051A8 (fr) Inhibiteurs d'ip6k
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
WO2018194181A8 (fr) Composés hétérocycliques utiles en tant que modulateurs des récepteurs de l'acétylcholine
MA62175B1 (fr) Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase
ATE553077T1 (de) Peptidaseinhibitoren
MA31386B1 (fr) Composé bicyclique et son utilisation pharmaceutique
SA522441231B1 (ar) مركبات (تراي فلورو ميثيل) بيريميدين-2-أمين.